Risk Of Developing Liver Cancer After HCV Treatment

Sunday, February 15, 2015

Gilead Faces Challenge For Hepatitis C Drug Patent

Gilead Faces Challenge For Hepatitis C Drug Patent
By sonali raj February 15 2015 10:26 PM

Gilead is facing a challenge to its hepatitis C drug in Europe. A medical aid is challenging its patent for the popular drug Sovaldi on claims that Gilead is abusing its patent by charging an exorbitant price for the drug, making it inaccessible to many patients.

Medicins du Monde, the charity that has challenged the drug patent, says that the nearly $50,000 cost is out of reach for most patients in Europe. Between 7.3 and 8.8 million people are believed to be infected with hepatitis C in Europe. The director of Medicins du Monde said that even in a wealthy country like France, with an annual medicines budget of $30 billion, the cost is not easy to meet.


No comments:

Post a Comment